Rösslein Matthias, Liptrott Neill J, Owen Andrew, Boisseau Patrick, Wick Peter, Herrmann Inge K
a Department Materials Meet Life , Swiss Federal Laboratories for Materials Science and Technology (Empa) , St. Gallen , Switzerland.
b Department of Molecular and Clinical Pharmacology , University of Liverpool , Liverpool , UK.
Nanotoxicology. 2017 Mar;11(2):147-149. doi: 10.1080/17435390.2017.1279361. Epub 2017 Jan 24.
Nanotechnology has transformed materials engineering. However, despite much excitement in the scientific community, translation of nanotechnology-based developments has suffered from significant translational gaps, particularly in the field of biomedicine. Of the many concepts investigated, very few have entered routine clinical application. Safety concerns and associated socioeconomic uncertainties, together with the lack of incentives for technology transfer, are undoubtedly imposing significant hurdles to effective clinical translation of potentially game-changing developments. Commercialisation aspects are only rarely considered in the early stages and in many cases, the market is not identified early on in the process, hence precluding market-oriented development. However, methodologies and in-depth understanding of mechanistic processes existing in the environmental, health and safety (EHS) community could be leveraged to accelerate translation. Here, we discuss the most important stepping stones for (nano)medicine development along with a number of suggestions to facilitate future translation.
纳米技术已经改变了材料工程。然而，尽管科学界对此充满热情，但基于纳米技术的发展在转化过程中仍存在重大差距，尤其是在生物医学领域。在众多研究的概念中，只有极少数进入了常规临床应用。安全问题、相关的社会经济不确定性，以及技术转让缺乏激励措施，无疑给可能带来变革性发展的有效临床转化带来了重大障碍。商业化方面在早期很少被考虑，而且在许多情况下，市场在过程早期未被识别，因此排除了以市场为导向的发展。然而，可以利用环境、健康与安全（EHS）领域现有的方法和对机理过程的深入理解来加速转化。在此，我们讨论（纳米）医学发展的最重要的垫脚石以及一些促进未来转化的建议。
